Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Huntington's disease with OSU 6162 – pilot study
2009-015926-13Phase 2Completed
- Sponsor
- Sahlgrenska University Hospital
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OSU-6162 in Huntington disease (HD), sponsored by Sahlgrenska University Hospital. Primary endpoints: Therapeutic effects on motor, cognitive, behavioral, and functional outcomes and Cognitive performance by Trail Making Test A. Started Dec 2009; status: completed.
02
Drugs
OSU-6162
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2009-015926-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015926-13.